Logo for Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Investor Relations Material

Latest events

Logo for Tarsus Pharmaceuticals Inc

Q2 2024

Tarsus Pharmaceuticals
Logo for Tarsus Pharmaceuticals

Q2 2024

8 Aug, 2024
Logo for Tarsus Pharmaceuticals

Q1 2024

8 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Tarsus Pharmaceuticals Inc

Access all reports
Tarsus Pharmaceuticals Inc. is a biopharmaceutical company primarily engaged in the development and commercialization of novel therapeutic candidates targeted at various ophthalmic conditions. Its leading product candidate, TP-03, is a novel therapy aimed at treating blepharitis caused by the infestation of Demodex mites and is also being developed to address meibomian gland disease. Furthermore, the company is working on TP-04 for the treatment of rosacea and TP-05, an oral tablet intended for the prevention of Lyme disease and community malaria reduction. Tarsus Pharmaceuticals Inc. is headquartered in Irvine, California, and its shares are listed on the Nasdaq.